Itaconate may be downregulated through the overexpression of CLYBL in COVID-19 patients (IMAGE)

Science China Press

Itaconate may be downregulated through the overexpression of CLYBL in COVID-19 patients

Caption

Overexpression of CLYBL could lead to the loss of upstream metabolites, thus resulting in the reduction of itaconate. Itaconate can inhibit succinate dehydrogenase (SDH), activate NRF2/NFE2L2 via alkylation of KEAP1, and inhibit caspase-1-mediated cleavage of IL-1β and IL-18 to avoid excessive inflammation via the blockage of NLRP3 inflammasome activation.

Credit

©Science China Press

Usage Restrictions

Use with credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.